Health

Danaher had a disappointing 2024. Its path to success next year goes through Wall Street


Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.